Blueprint Medicines Corporation
http://www.blueprintmedicines.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
BeiGene’s Brukinsa Among Five Orphan Drugs Awaiting EU Approval Verdict
Sponsors of several new medicines are set to learn if their products are on track for pan-EU approval. One product on the list is Pfizer/Lilly’s osteoarthritis drug, tanezumab, which recently ran into trouble in the US.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Hoyle Pharmaceuticals, Inc.
- ImmunoCo, Inc.